Aventis Apidra Clears FDA; Rapid-Acting Insulin Launch Awaits Delivery Device Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis will wait until the OptiClick delivery device is approved before launching Apidra; the company filed for approval of the device in February. The rapid-acting insulin is approved by FDA April 16.
You may also be interested in...
Aventis Lantus Approved For Use With Insulin Delivery Device
The OptiClick reusable “pen” injection system will be used with insulin products Lantus, Apidra; both had been approved for subcutaneous injection. Aventis has not announced its launch plans for OptiClick.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.